New drug duo tested to fight Tough-to-Treat cancers
NCT ID NCT03526679
Summary
This study tested the safety and effectiveness of combining two drugs, lenvatinib and eribulin, for treating advanced liposarcoma and leiomyosarcoma. It involved 30 patients whose cancer could not be surgically removed or had spread, and who had received up to two prior chemotherapy treatments. The goal was to see if this combination could better control tumor growth than previous standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan
Conditions
Explore the condition pages connected to this study.